AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01335828 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Medical ultrasound device (ShearWave system)
Description: Echography (all modes) and elastography ShearWave system
Study NCT02255877 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zip Surgical Skin Closure
Description: Non invasive skin closure device for closure of the skin layer for surgical incisions or laceration repair.
Study NCT02255877 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Steel Staples
Description: Skin Closure device for the closure of the skin layer for surgical incisions.
Study NCT01739244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYL040012
Description: Ocular topical administration of SYL040012 for 14 consecutive days
Study NCT01739244 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ocular topical administration of placebo for 14 consecutive days
Study NCT04657172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine Ophthalmic
Description: Pilocarpine 1% or 2% ophthalmic solution administered with the Optejet microdose dispenser
Study NCT04657172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle ophthalmic solution administered with the Optejet microdose dispenser
Study NCT02724956 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu AuraGain
Description: Pre-curved, rigid airway tube, SGAD. Third generation Ambu laryngeal mask satisfying 3 fundamental airway management needs by integrating gastric access and intubation capability in an anatomically curved single-use device that facilitates rapid establishment of a safe airway. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.
Study NCT01171313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet (comparator)
Description: Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed Sinemet.
Study NCT01171313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for XP21279 and carbidopa
Description: Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for XP21279 and carbidopa
Study NCT01171313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Sinemet
Description: Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for Sinemet
Study NCT02515188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propacetamol
Description: Randomly selected patients of the propacetamol group are given intravenous propacetamol 2g for 15 minutes on the beginning of the procedure.
Study NCT02515188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group are given intravenous Normal Saline 2g for 15 minutes on the beginning of the procedure.
Study NCT02545452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole / Levonorgestrel (BAY98-7196)
Description: Release rate of the IVR: 1050 μg/d ATZ + 40 μg/d LNG
Study NCT02545452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gyno-Daktarin
Description: 400 mg miconazole nitrate per day for 3 consecutive days
Study NCT00866190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is an oval, coated, white, scored tablet administered once daily for 14 days or on Days 1-5, 9, and 14.
Study NCT02545452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sobelin vaginal creme
Description: 100 mg clindamycin 2-dihydrogen phosphat per day for 3 consecutive days
Study NCT02545452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patentex oval
Description: 75 mg Nonoxynol-9 per day for 3 consecutive days
Study NCT02545452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tampon
Study NCT00117572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 75 mg/m2 on day 1 (induction phase); 25 mg/m2 on day 1 (chemoradiotherapy phase)
Study NCT00117572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: 75 mg/m2 on day 1
Study NCT00117572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxyurea
Description: Each cycle: 500 mg PO q 12 hours x 6 days (11 doses)
Study NCT00117572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: 750 mg/m2/day on days 1-5 (induction phase); 600 mg/m2/day, day 0-4 (chemoradiotherapy phase)
Study NCT00117572 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: See protocol for details
Study NCT03767335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEN1611
Description: MEN1611 oral dose administered twice daily for a continuous 28-day cycle
Study NCT00117572 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: See protocol for details
Study NCT02797470 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
Study NCT02797470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: 300 mg/m2 on Day -6, as part of BEAM and R-BEAM regimens.
Study NCT02797470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 100 mg/m2 BID on Days -5 through -2, as part of BEAM and R-BEAM regimens.
Study NCT02797470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: VP-16: 100 mg/m2 BID on Days -5 through -2, as part of BEAM and R-BEAM regimens.
Study NCT02724956 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Teleflex LMA Protector
Description: Pre-curved, rigid airway tube, SGAD: A next-generation, single-use laryngeal mask with a dual gastric drainage channel and pharyngeal chamber. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.
Study NCT02724956 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu aScope
Description: Flexible scope which will be introduced into airway tube and guided through the SGAD until it will be possible to view the vocal cords. Description of the maximal optical view will be measured by the Percentage of Glottic Opening (POGO).
Study NCT03767335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab solution for infusion administered weekly via IV
Study NCT03767335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant solution for injection administered monthly via IM (only for HR-positive postmenopausal women)
Study NCT02472327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-operative support
Study NCT04472793 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2
Description: 1. Testing weekly samples from nasal swabs to promptly diagnose acute COVID-19 infection.~2. Testing monthly serum samples to document post-viral infection.
Study NCT00798148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131I-MIBG , Etoposide, Melphalan, Carboplatin, Autologous Peripheral Stem Cell Transplantation
Description: 131I-MIBG 12mci/kg CEM(Etoposide)=1200mg/m2 Melphalan=210mg/m2 Carboplatin=1500mg/m2 Autologous Peripheral Stem Cell Transplantation
Study NCT02293863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHAA4549A
Description: Participants will receive a single dose of MHAA4549A by IV infusion on Day 1
Study NCT02293863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Participants will receive oseltamivir capsule either 75 mg or 150 mg BID orally for minimum of 5 days. Dosage and administration should follow local prescribing information for oseltamivir.
Study NCT02293863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oseltamivir
Description: Participants will receive oseltamivir capsule either 75 mg or 150 mg BID orally for minimum of 5 days. Dosage and administration should follow local prescribing information for oseltamivir.
Study NCT02293863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single IV dose of placebo matched to MHAA4549A on Day 1
Study NCT02797470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02797470 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells
Description: Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
Study NCT02797470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m2 on Day -1, as part of BEAM and R-BEAM regimens.
Study NCT02797470 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
Study NCT02365194 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Prehabilitation
Description: information included in arm description
Study NCT02365194 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard counseling
Description: information included in arm description
Study NCT02470533 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: 6 fractions of 8-9Gy
Study NCT02470533 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: chemoembolization
Description: Up to 4 sessions
Study NCT02784444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MSDC-0602K
Description: MSDC-0602K capsules
Study NCT02784444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT01286935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide
Study NCT01111513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 48-hour ropivacaine infusions
Description: Patients receive 20 ml of ropivacaine 0.5 % pre-operation through femoral block catheter, followed by ropivacaine infusions from 0.1 % to 0.1 ml/kg/hour for 48 hours.
Study NCT03745404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 5% medicated Plaster
Study NCT03745404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Plaster
Study NCT00668850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generex Oral-lyn™
Description: Generex Oral-lyn™ spray in a split-dose fashion (half the dose immediately prior to the meal and half the dose immediately after the meal) + BID NPH insulin AM and PM as pre-randomization dose
Study NCT01111513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single dose ropivacaine
Description: Patients receive 20 ml of ropivacaine 0.5% pre-operation
Study NCT01111513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient controlled analgesics
Description: Patient controlled analgesics alone, no femoral block
Study NCT00262782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine i.v. (25 mg/m2/d, d1-5) q28d; max 6 cycles
Study NCT04010435 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: high frequency (10 HZ) rTMS pulses are applied to the dorsolateral prefrontal cortex of the dominant hemisphere.
Study NCT00668850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular human insulin
Description: Regular human insulin 30 minutes before meals + BID NPH insulin AM and PM as pre-randomization dose.
Study NCT03174769 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal protein
Description: Following a two week baseline assessment period, subjects will consume a diet with normal protein diet while undergoing weight loss for 12 wk.
Study NCT03174769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High protien
Description: Following a two week baseline assessment period, subjects will consume a diet with high protein diet while undergoing weight loss for 12 wk.
Study NCT01286935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03604315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo FDG PET/CT
Study NCT02652546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Assess Safety
Description: Assess the safety of a 12-week course if CC-1150 in HIV-infected adults who have been on ART for greater than or equal to 1 year and have suppressed plasma viremia
Study NCT03604315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo \[18F\]FTT PET/CT
Study NCT03604315 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given IV
Study NCT03604315 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 Fluorthanatrace
Description: Given IV
Study NCT02652546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Assess Safety
Description: Assess the safety of a 12-week course if CC-1150 in HIV-infected adults who have been on ART for greater than or equal to 1 year and have suppressed plasma viremia
Study NCT02652546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Effect of drug on viral load
Description: Evaluate the effect of CC-11050 on plasma HIV-1 RNA levels by both conventional and single copy assay at week 12 and over all evaluable time points
Study NCT02652546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Effect of drug on T-cell count
Description: Evaluate the effect of CC-11050 on CD4+ T cell counts and percentages at week 12 and over all evaluable time points
Study NCT02652546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Effect of drug on inflammatory biomarkers
Description: Evaluate the effect of CC-11050 on markers of markers of systemic inflammation (TNF, IL-\^, CRP, IFNg, sCD14, D-dimer) at week 12 and over all evaluable time points.
Study NCT04135664 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: esophagectomy
Description: esophagectomy with at least two-field (thoracic-abdominal) lymphadenectomy
Study NCT03604315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG PET/CT
Study NCT03604315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo \[18F\]FTT PET/CT
Study NCT04010435 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Galvanic stimulation
Description: galvanic stimulation of the vestibular apparatus
Study NCT03118323 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Patients are given a questionnaire with items related to personality and their willingness-to-pay for different treatment options.
Study NCT01334489 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Arabin Cervical Pessary
Description: The Arabin cervical pessary, which is CE-certified for preventing SPB (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC).~It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain.
Study NCT01639131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: intravenous gemcitabine 800mg/m2 on days 1 and 8
Study NCT02530658 — intervention group
Intervention type: OTHER
Intervention: Study Introduction Visit
Description: Within 5±3 weeks following arrival at SJCRH, or at the participant/family's convenience, participants will meet with a genetic counselor and clinician, provide information for a family pedigree, undergo a physical and discuss germline testing options. Study introduction materials will be provided. Families interested in the G4K study will be referred to the study nurse or other G4K member and an Informed consent visit will be scheduled.
Study NCT02530658 — intervention group
Intervention type: OTHER
Intervention: Informed Consent Visit
Description: Within 1±3 weeks following the Study Introduction Visit, or at the participant/family's convenience, the research nurse or other study team member will consent the family and collect demographic and medical information. Participants will complete assessment questionnaires.
Study NCT04135664 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: chemoradiation
Description: concurrent chemotherapy and radiotherapy
Study NCT04135664 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: chemoradiation
Description: concurrent chemotherapy and radiotherapy
Study NCT04135664 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: active surveillance
Description: No further adjuvant therapy
Study NCT04683133 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Optical coherence tomography assessment
Description: Optical coherence tomography assessment of coronary arteries with intermediate to severe stenosis
Study NCT01715090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Web-based insulin titration
Study NCT03625960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cantharidin
Description: A thin film of cantharidin is applied to the surface of the wart and to 1 millimeter area surrounding the wart. After the film dries, it is covered with an occlusive dressing for 24 hours. The patient removes the area the next day and thoroughly washes the area with soap and water. Patients return to clinic a week later.
Study NCT03625960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trichloroacetic Acid
Description: Trichloroacetic acid is applied to the surface of the wart with a wooden applicator and after drying the area is washed with soap and water in an hour.
Study NCT00591175 — intervention group
Intervention type: BEHAVIORAL
Intervention: Standard Care only
Description: Dentist Provided Standard Care, 3-month follow-up assessment, Clinic visit salivary cotinine test, 12-month follow-up assessment, Clinic visit salivary cotinine test
Study NCT00591175 — intervention group
Intervention type: BEHAVIORAL
Intervention: Dental Hygienist provided counseling + Brief Questionnaire
Description: Dental Hygienist provided + Brief Questionnaire, 3-month follow-up assessment,Clinic visit salivary cotinine test, 12-month follow-up, Clinic visit salivary cotinine test assessment
Study NCT00591175 — intervention group
Intervention type: BEHAVIORAL
Intervention: Dental Hygienist provided counseling with personalized risk communication + Brief Questionnaire
Description: Dental Hygienist provided counseling with personalized risk communication + Brief Questionnaire, 3-month follow-up assessment, Clinic visit salivary cotinine test, 12-month follow-up assessment, Clinic visit salivary cotinine test
Study NCT01896414 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA (marine fatty acids)
Description: Subjects will be randomized to receive either EPA or placebo, four 1 gram capsules daily.
Study NCT01896414 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized to receive either EPA/ or placebo, four 1 gram capsules daily.
Study NCT00205946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: 150 mg of bupropion administered 5 hours before fMRI scanning
Study NCT01639131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: intravenous docetaxel 70mg/m2 on day 8 of each 21 day cycle
Study NCT01639131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim or Pegfilgrastim
Description: filgrastim (granulocyte colony-stimulating factor \[G-CSF\]) on days 9 through 15 or pegfilgrastim 6 mg on day 9 or 10 of each cycle
Study NCT01921075 — intervention group
Intervention type: OTHER
Intervention: normal dietary behavior
Description: normal dietary behavior during examination days
Study NCT01921075 — intervention group
Intervention type: OTHER
Intervention: Magnetic resonance spectroscopy
Description: Non-invasive diagnostic procedure
Study NCT03851367 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sling suspension using red cord
Description: 3 weeks duration, 15 sessions, and 30 minutes a day for five consecutive days a week. Back pain, endurance of trunk muscles (flexors, extensors and side flexors), and standing posture were evaluated pre and post interventions.
Study NCT00205946 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered 5 hours prior to fMRI scanning (randomly assigned, double blind)
Study NCT03607149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: standard arm : calculating the dose of pemetrexed according to body surface area~experimental arm: calculation of the dose of pemetrexed as a function of creatinine clearance (CrCLCG)